注射爱尔兰爵士制药的去纤维钠需要注意什么？

Ireland's Jazz Pharmaceuticals is a professional biopharmaceutical company whose products include. Defibrinated sodium is indicated for patients with hepatic veno-occlusive disease (VOD).

The recommended dose of defibrotide sodium for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Administer defibrinated sodium for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Defibrinated sodium must be diluted before infusion. Prior to administration of defibrinated sodium, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Administer defibrinated sodium by constant intravenous infusion over a 2-hour period.

What should I pay attention to when injecting Irish Jazz Pharmaceuticals' defibrinated sodium?

Defibrinated sodium increases plasmin activity in vitro, and sputum may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding. If bleeding occurs in a patient taking DEFITELIO, discontinue defibrotide, treat the cause, and provide supportive care until bleeding has stopped.

Hypersensitivity reactions have occurred in less than 2% of treated patients. These reactions include rash, urticaria, and angioedema. One case of anaphylactic reaction was reported in a patient who had previously received defibrotide. Monitor patients for hypersensitivity reactions. Especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat with standard medical care, and monitor until symptoms resolve.

Recommended related hot articles: /newsDetail/92888.html